ASCO: Targeted Tx Combo Stalls NSCLC

CHICAGO (MedPage Today) -- Adding bevacizumab (Avastin) to first-line targeted therapy delayed progression in a subgroup of non-small cell lung cancer (NSCLC), an open-label trial showed.
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news